Blueprint Medicines Corp. (BPMC)

84.06
NASDAQ : Health Technology
Prev Close 81.73
Day Low/High 82.11 / 84.93
52 Wk Low/High 44.58 / 102.98
Avg Volume 473.80K
Exchange NASDAQ
Shares Outstanding 49.12M
Market Cap 4.01B
EPS -5.40
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Blueprint Medicines Reports Second Quarter 2019 Financial Results

Blueprint Medicines Reports Second Quarter 2019 Financial Results

-- NDA and MAA submitted for avapritinib for defined GIST patient populations --

Blueprint Medicines To Report Second Quarter 2019 Financial Results On Thursday, August 1, 2019

Blueprint Medicines To Report Second Quarter 2019 Financial Results On Thursday, August 1, 2019

CAMBRIDGE, Mass., July 25, 2019 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that it will host a live conference...

Blueprint Medicines Announces European Medicines Agency Validation Of Marketing Authorization Application For Avapritinib For The Treatment Of PDGFRα D842V Mutant GIST And Fourth-Line GIST

Blueprint Medicines Announces European Medicines Agency Validation Of Marketing Authorization Application For Avapritinib For The Treatment Of PDGFRα D842V Mutant GIST And Fourth-Line GIST

CAMBRIDGE, Mass., July 18, 2019 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that the European Medicines Agency...

Blueprint Medicines Submits New Drug Application To U.S. Food And Drug Administration For Avapritinib For The Treatment Of PDGFRA Exon 18 Mutant GIST And Fourth-Line GIST

Blueprint Medicines Submits New Drug Application To U.S. Food And Drug Administration For Avapritinib For The Treatment Of PDGFRA Exon 18 Mutant GIST And Fourth-Line GIST

CAMBRIDGE, Mass., June 14, 2019 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced it has submitted a New Drug...

Blueprint Medicines' Highly Selective RET Inhibitor BLU-667 Shows Durable Anti-Tumor Activity In Patients With RET-Altered Cancers In Updated ARROW Trial Data Presented At ASCO 2019

Blueprint Medicines' Highly Selective RET Inhibitor BLU-667 Shows Durable Anti-Tumor Activity In Patients With RET-Altered Cancers In Updated ARROW Trial Data Presented At ASCO 2019

-- 60% ORR in post-platinum RET-fusion NSCLC and 63% ORR in RET-mutant MTC patients previously treated with multi-kinase inhibitors; median durations of response not reached -- -- Responses observed across treatment-naïve and previously treated patients,...

Blueprint Medicines To Present At Upcoming Investor Conferences In June

Blueprint Medicines To Present At Upcoming Investor Conferences In June

CAMBRIDGE, Mass., May 29, 2019 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy,  today announced its participation in the following...

Blueprint Medicines Reports First Quarter 2019 Financial Results

Blueprint Medicines Reports First Quarter 2019 Financial Results

-- Avapritinib NDA for PDGFRA Exon 18 mutant GIST and fourth-line GIST on track for submission to FDA in second quarter --

Blueprint Medicines To Present At Bank Of America Merrill Lynch 2019 Health Care Conference

Blueprint Medicines To Present At Bank Of America Merrill Lynch 2019 Health Care Conference

CAMBRIDGE, Mass., May 8, 2019 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy,  today announced that Jeff Albers, Blueprint...

Blueprint Medicines To Report First Quarter 2019 Financial Results On Thursday, May 9, 2019

Blueprint Medicines To Report First Quarter 2019 Financial Results On Thursday, May 9, 2019

CAMBRIDGE, Mass., May 2, 2019 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that it will host a live conference...

Blueprint Medicines Announces Closing Of Public Offering And Full Exercise Of Option To Purchase Additional Shares Of Common Stock

Blueprint Medicines Announces Closing Of Public Offering And Full Exercise Of Option To Purchase Additional Shares Of Common Stock

CAMBRIDGE, Mass., April 2, 2019 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced the closing of its previously...

Blueprint Medicines Announces Pricing Of Public Offering Of Shares Of Common Stock

Blueprint Medicines Announces Pricing Of Public Offering Of Shares Of Common Stock

CAMBRIDGE, Mass., March 28, 2019 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced the pricing of an underwritten...

Blueprint Medicines Announces Proposed Public Offering Of Shares Of Common Stock

Blueprint Medicines Announces Proposed Public Offering Of Shares Of Common Stock

CAMBRIDGE, Mass., March 27, 2019 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that it has commenced an...

Blueprint Medicines Announces Accelerated Regulatory Submission Plans And Recent Clinical Progress

Blueprint Medicines Announces Accelerated Regulatory Submission Plans And Recent Clinical Progress

-- Avapritinib: plan to submit MAA for PDGFRα D842V mutant GIST and fourth-line GIST in Q3 2019 and NDA for advanced systemic mastocytosis in Q1 2020 --

Blueprint Medicines To Present At 39th Annual Cowen & Co. Health Care Conference

Blueprint Medicines To Present At 39th Annual Cowen & Co. Health Care Conference

CAMBRIDGE, Mass., March 5, 2019 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy,  today announced that Jeff Albers, Blueprint...

Blueprint Medicines Reports Fourth Quarter And Full Year 2018 Financial Results

Blueprint Medicines Reports Fourth Quarter And Full Year 2018 Financial Results

-- Avapritinib NDA for PDGFRA Exon 18 mutant GIST and fourth-line GIST on track for submission to FDA in second quarter --

First Week Of BPMC July 2019 Options Trading

First Week Of BPMC July 2019 Options Trading

Investors in Blueprint Medicines Corp saw new options become available this week, for the July 2019 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 207 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Blueprint Medicines Corp Larger Than S&P 500 Component News Corp

Blueprint Medicines Corp Larger Than S&P 500 Component News Corp

In the latest look at stocks ordered by largest market capitalization, Russell 3000 component Blueprint Medicines Corp was identified as having a larger market cap than the smaller end of the S&P 500, for example News Corp , according to The Online Investor. Market capitalization is an important data point for investors to keep an eye on, for various reasons.

Watch Oncology Stocks Ahead of 2 Big Events

Watch Oncology Stocks Ahead of 2 Big Events

Data and industry conferences will likely be catalysts for shares in the space.

First Week Of BPMC February 2018 Options Trading

First Week Of BPMC February 2018 Options Trading

Investors in Blueprint Medicines Corp saw new options become available this week, for the February 2018 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the BPMC options chain for the new February 2018 contracts and identified one put and one call contract of particular interest.

Blueprint Medicines and Bluebird Bio Soar on ASH Announcements -- Biotech Movers

Blueprint Medicines and Bluebird Bio Soar on ASH Announcements -- Biotech Movers

Blueprint unveiled new data from its ongoing Phase 1 study of avapritinib in advanced systemic mastocytosis at the 59th American Society of Hematology Annual Meeting.

Blueprint Medicines Reaches Analyst Target Price

Blueprint Medicines Reaches Analyst Target Price

In recent trading, shares of Blueprint Medicines Corp have crossed above the average analyst 12-month target price of $55.60, changing hands for $55.95/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Blueprint Medicines Becomes Oversold (BPMC)

Blueprint Medicines Becomes Oversold (BPMC)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Interesting BPMC Put And Call Options For August 18th

Interesting BPMC Put And Call Options For August 18th

Investors in Blueprint Medicines Corp saw new options begin trading this week, for the August 18th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the BPMC options chain for the new August 18th contracts and identified one put and one call contract of particular interest.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AIG, ALSK, GNE, GUID, HTH, LPI, NUVA, PIRS, QRVO, S, TTMI Downgrades: ARRS, BPMC, CONE, CRAY, EFII, GIL, GKOS, HYH, SUM Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

TheStreet Quant Rating: D (Sell)